Long-term QoL in Acute Promyelocytic Leukemia Treated With ATO or Standard Chemotherapy

Long-term Quality of Life Symptom Burden in Acute Promyelocytic Leukemia (APL) Patients Treated With Arsenic Trioxide (ATO) or Standard Chemotherapy

This is a prospective and international observational study run by the GIMEMA. All data will be centrally collected and analyzed at the GIMEMA Data Center in Rome (Italy). Patients reported outcomes will be collected using internationally validated questionnaires.

Inclusion Criteria:

• APL survivors enrolled in GIMEMA APL0406 clinical trial and in first molecular CR after third consolidation treatment
• Written informed consent.

Exclusion Criteria:

• APL patients previously enrolled in GIMEMA APL0406 trial who cannot be reached or who are lost to follow-up.